

Resource Summary Report

Generated by [dkNET](#) on Sep 9, 2026

Brilliant Violet 570(TM) anti-mouse CD45

RRID:AB_2562612

Type: Antibody

Proper Citation

BioLegend Cat# 103136, RRID:AB_2562612

Antibody Information

URL: http://antibodyregistry.org/AB_2562612

Proper Citation: BioLegend Cat# 103136, RRID:AB_2562612

Target Antigen: CD45

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 570(TM) anti-mouse CD45

Description: This monoclonal targets CD45

Target Organism: mouse

Clone ID: Clone 30-F11

Antibody ID: AB_2562612

Vendor: BioLegend

Catalog Number: 103136

Alternative Catalog Numbers: 103135

Record Creation Time: 20231110T035221+0000

Record Last Update: 20260901T063731+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 570(TM) anti-mouse CD45.

No alerts have been found for Brilliant Violet 570(TM) anti-mouse CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Mitra T, et al. (2026) MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion. *Immunity*.

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. *iScience*, 29(5), 115669.

Myers JA, et al. (2026) E-cadherin expression promotes tumor growth via KLRG1-dependent pathways. *Journal of immunology (Baltimore, Md. : 1950)*, 215(4).

Zhao L, et al. (2026) Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer. *NPJ precision oncology*.

Huang X, et al. (2026) Opposing functions of distinct regulatory T cell subsets in colorectal cancer. *Immunity*, 59(1), 145.

Cook DR, et al. (2025) Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM. *Frontiers in immunology*, 16, 1579925.

Mitra T, et al. (2025) MEK-dependent bioenergetic demand drives terminal CD8 + T cell exhaustion. *bioRxiv : the preprint server for biology*.

Skelly DA, et al. (2025) Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response. *Cell reports*, 44(5), 115698.

Reilly SP, et al. (2025) Unconventional CD8+ T cell surveillance of cytomegalovirus via Qa-1/HLA-E-restricted epitope recognition. *Science advances*, 11(51), eaea8707.

Liu ZY, et al. (2025) Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. *Immunity*, 58(6), 1572.

Tzeng SF, et al. (2025) PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis. *Cancer discovery*, 15(8), 1676.

Subramanian S, et al. (2024) Microbiota regulates neonatal disease tolerance to virus-evoked necrotizing enterocolitis by shaping the STAT1-NLRC5 axis in the intestinal epithelium. *Cell host & microbe*, 32(10), 1805.

Sprooten J, et al. (2024) Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells. *Cell reports. Medicine*, 5(1), 101377.

Zohaib Ali M, et al. (2024) A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. *eLife*, 13.

Lindner S, et al. (2024) Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease. *Nature microbiology*, 9(3), 614.

Borys SM, et al. (2024) NK cells restrain cytotoxic CD8+ T cells in the submandibular gland via PD-1-PD-L1. *Science immunology*, 9(102), eadl2967.

Huang CX, et al. (2024) Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. *Cancer cell*, 42(12), 2082.

Wu RQ, et al. (2023) Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. *Immunity*, 56(1), 180.

Chang YW, et al. (2023) A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8+ T cells. *Cell reports. Medicine*, 4(8), 101154.

Dutt TS, et al. (2022) Mucosal exposure to non-tuberculous mycobacteria elicits B cell-mediated immunity against pulmonary tuberculosis. *Cell reports*, 41(11), 111783.